NCT05588219View on ClinicalTrials.gov

Tislelizumab Combined With Concurrent Chemoradiotherapy for Locally Advanced Cervical Cancer

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

December 1, 2022

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2025

Conditions
Uterine Cervical Neoplasms
Interventions
DRUG

Tislelizumab

Tislelizumab injection\[10ml:100mg\] will be used beginning with radiotherapy: 200mg/3W for 1 year or disease progression or intolerable toxicity, whichever occurs first.

DRUG

DDP synchronous with radiotherapy

DDP 40mg/m2/W, synchronous with radiotherapy, complete at least 4 cycles.

Trial Locations (1)

530021

RECRUITING

First Affiliated Hospital of Guangxi Medical University, Nanning

All Listed Sponsors
lead

Yong Zhang,MD

OTHER